Testicular Cancer Pipeline Review, H2 2012


#146161

54pages

Global Markets Direct

$ 2000

In Stock

 

Global Markets Directs, 'Testicular Cancer Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Testicular Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Testicular Cancer. Testicular Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Testicular Cancer.
  • A review of the Testicular Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Testicular Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.
Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Testicular Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Testicular Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5

Introduction 6
Global Markets Direct Report Coverage 6
Testicular Cancer Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Testicular Cancer 8
Testicular Cancer Therapeutics under Development by Companies 10
Testicular Cancer Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Early Clinical Stage Products 15
Comparative Analysis 15
Discovery and Pre-Clinical Stage Products 16
Comparative Analysis 16
Testicular Cancer Therapeutics Products under Development by Companies 17
Testicular Cancer Therapeutics Products under Investigation by Universities/Institutes 18
Companies Involved in Testicular Cancer Therapeutics Development 19
NsGene A/S 19
ZIOPHARM Oncology, Inc. 20
Cell Therapeutics, Inc. 21
Testicular Cancer Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Combination Products 23
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
NsG-6 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Cisplatin + Etoposide - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Paclitaxel + Gemcitabine - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
carboplatin - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Cisplatinum + Vinblastine + Bleomycin - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
CBOP + BEP - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 34
Carboplatin + Cisplatin + Cyclophosphamide + Etoposide + Ifosfamide + Vinblastine + Autologous Bone marrow Transplantation - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Filgrastim + Carboplatin + Etoposide + Ifosfamide + Paclitaxel + Autologous Bone Marrow Transplantation - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Dasatinib + Ifosfamide + Carboplatin + Etoposide - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 40
Cisplatin + Paclitaxel + Gemcitabine - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 42
Amsacrine + Cisplatin - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Etoposide + Cyclophosphamide + Cisplatin - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
palifosfamide + etoposide + carboplatin - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
CT-47613 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Carboplatin + Gemcitabine Hydrochloride - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Testicular Cancer Therapeutics Drug Profile Updates 49
Testicular Cancer Therapeutics Discontinued Products 50
Testicular Cancer Therapeutics - Dormant Products 51

Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 54
Disclaimer 54
 
Number of Products Under Development for Testicular Cancer, H2 2012 8
Products under Development for Testicular Cancer Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 10
Number of Products under Investigation by Universities/Institutes, H2 2012 12
Comparative Analysis by Late Stage Development, H2 2012 13
Comparative Analysis by Mid Clinical Stage Development, H2 2012 14
Comparative Analysis by Early Clinical Stage Development, H2 2012 15
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 16
Products under Development by Companies, H2 2012 17
Products under Investigation by Universities/Institutes, H2 2012 18
NsGene A/S, H2 2012 19
ZIOPHARM Oncology, Inc., H2 2012 20
Cell Therapeutics, Inc., H2 2012 21
Assessment by Monotherapy Products, H2 2012 22
Assessment by Combination Products, H2 2012 23
Assessment by Stage and Route of Administration, H2 2012 25
Assessment by Stage and Molecule Type, H2 2012 27
Testicular Cancer Therapeutics Drug Profile Updates 49
Testicular Cancer Therapeutics Discontinued Products 50
Testicular Cancer Therapeutics Dormant Products 51 
Number of Products under Development for Testicular Cancer, H2 2012 8
Products under Development for Testicular Cancer Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 11
Late Stage Products, H2 2012 13
Mid Clinical Stage Products, H2 2012 14
Early Clinical Stage Products, H2 2012 15
Discovery and Pre-Clinical Stage Products, H2 2012 16
Assessment by Monotherapy Products, H2 2012 22
Assessment by Combination Products, H2 2012 23
Assessment by Route of Administration, H2 2012 24
Assessment by Stage and Route of Administration, H2 2012 25
Assessment by Molecule Type, H2 2012 26
Assessment by Stage and Molecule Type, H2 2012 27